US General Anesthesia Drugs Market Growth, Trends, Size, Demand, Revenue and Future Outlook
US General Anesthesia Drugs Market Size- By Route of Administration, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Jan-2024 | Report ID: PHAR2402 | Pages: 1 - 106 | Formats*: |
| Category : Pharmaceutical | |||
US General Anesthesia Drugs Market Introduction and Overview
According to SPER Market Research, the US General Anesthesia Drugs Market is estimated to reach USD 3.18 Billion by 2033 with a CAGR of 3.6%.
The report includes an in-depth analysis of the US General Anesthesia Drugs Market, including market size and trends, product mix, applications, and supplier analysis. The purpose of a general anaesthesia medication is to induce and maintain unconsciousness and the lack of pain perception. It essentially involves an inducible condition of unconsciousness combined with a partial or total absence of defensive reflexes. It is taken by inhalation or intravenous means in conjunction with drugs. Some intravenous general anaesthetic medications include propofol, etiomide, and ketamine; inhalation anaesthesia medications include sevoflurane and desflurane. Numerous heart procedures, hip and knee replacement surgeries, cancer surgeries, and gastrointestinal surgeries all include the use of general anaesthesia.
- 2020: Radio-frequency identification technology was integrated into smart labels for the first time by Fresenius Kabi in 2020. Diprivan (Propofol) 200 mg per 20 mL (10 mg per mL) Injectable Emulsion, USP, the first RFID smart-labeled pharmaceutical, was released in the US.
- 2020: 2020 saw the US debut of the Propofol Injectable Emulsion, USP, in vials of 20 mL, 50 mL, and 100 mL by Hikma Pharmaceuticals USA Inc.
Market Opportunities and Challenges
Opportunity: Patent expiry of Lusedra Fospropofol disodium, sometimes known as Lusedra, is an intravenous sedative-hypnotic drug. In 2008, the FDA authorised it for use in adult patients undergoing therapeutic or diagnostic procedures as managed anaesthesia care (MAC) sedation. By 2022, this chemical will lose its patent. This molecule's patent expiration will open the door for generic medications to join the US market, which should provide a strong growth opportunity for the major market participants.
Challenge: Dangers of general anaesthesia in young patients and expectant mothers
Regarding the use of sedatives and general anaesthetics in young children and pregnant women, the US FDA released cautions in April 2017. Although the FDA highlighted concerns about the possible dangers associated with repeated or prolonged use, particularly in children under three years old and pregnant women, these medicines are necessary for surgical and stressful treatments in these populations. This prudence could lead to a decline in the adoption of general anaesthesia medications among medical professionals, which could potentially impede the expansion of the market. Healthcare professionals should carefully examine the risks and benefits, taking into account the FDA's cautions that may affect the use of certain medications in particular patient populations.
Market Competitive Landscape
The major key players in the US General Anesthesia Drugs Market are: Abbott Laboratories, AbbVie, Akorn, AstraZeneca plc, Baxter International Inc., Gilead Sciences, Inc, Heritage Pharmaceuticals Inc., Novartis AG, Par Pharmaceutical, Pfizer Inc., Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Route of Administration, By End User |
| Regions covered |
|
| Companies Covered | Abbott Laboratories, AbbVie, Akorn, AstraZeneca plc, Baxter International Inc., Gilead Sciences, Inc, Heritage Pharmaceuticals Inc., Novartis AG, Par Pharmaceutical, Pfizer Inc., Others |
COVID-19 Impact on US General Anesthesia Drugs Market
The market for general anaesthesia drugs is predicted to suffer as a result of the COVID-19 pandemic, as healthcare systems would be strained and demand will drop as a result of elective surgery postponement or cancellation. Patients with recent or continuing COVID-19 infections are more likely to experience post-operative problems and death, according to a February 2023 paper published in a review for Medical and Pharmacological Sciences. The use of anaesthesia is further complicated by the impossibility of a safe interval between COVID-19 therapy and surgery, as well as possible drug interactions. However, as delayed elective procedures become more common, the need of anaesthetic medications rises as things gradually get back to normal.
Key Target Audience:
- Pharmaceutical Companies
- Hospitals and Clinics
- Anesthesiologists and Anesthesia Providers
- Medical Device Companies
- Government Health Departments
- Distributors and Suppliers
- Others
Our in-depth analysis of the US General Anesthesia Drugs Market includes the following segments:
| By Route of Administration: |
|
| By End User: |
|
| By Region: |
|
Key Topics Covered in the Report:
- US General Anesthesia Drugs Market Size (FY’2023-FY’2033)
- Overview of US General Anesthesia Drugs Market
- Segmentation of US General Anesthesia Drugs Market By Route of Administration (Inhalational, and Intravenous)
- Segmentation of US General Anesthesia Drugs Market By End User (Ambulatory Surgery Centres, Hospitals)
- Statistical Snap of US General Anesthesia Drugs Market
- Expansion Analysis of US General Anesthesia Drugs Market
- Problems and Obstacles in US General Anesthesia Drugs Market
- Competitive Landscape in the US General Anesthesia Drugs Market
- Impact of COVID-19 and Demonetization on US General Anesthesia Drugs Market
- Details on Current Investment in US General Anesthesia Drugs Market
- Competitive Analysis of US General Anesthesia Drugs Market
- Prominent Players in the US General Anesthesia Drugs Market
- SWOT Analysis of US General Anesthesia Drugs Market
- US General Anesthesia Drugs Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges4.2. COVID-19 Impacts of the US General Anesthesia Drugs Market
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6. Competitive Landscape
6.1. US General Anesthesia Drugs Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in US General Anesthesia Drugs Market
7. US General Anesthesia Drugs Market, By Route of Administration (USD Million)
7.1. US General Anesthesia Drugs Market Value Share and Forecast, By Route of Administration, 2023-2033
7.2. Inhalational7.2.1. Desflurane7.2.2. Isoflurane7.2.3. Nitrous Oxide7.2.4. Sevoflurane7.3. Intravenous7.3.1. Benzodiazepines7.3.2. Etomidate7.3.3. Fentanyl7.3.4. Ketamine7.3.5. Methohexital Sodium7.3.6. Propofol7.3.7. Remifentanil7.3.8. Others
8. US General Anesthesia Drugs Market, By End User (USD Million)
8.1. US General Anesthesia Drugs Market Value Share and Forecast, By End User, 2023-20338.2. Ambulatory Surgery Centres8.3. Hospitals
9. US General Anesthesia Drugs Market Forecast, 2019-2033 (USD Million)
9.1. US General Anesthesia Drugs Market Size and Market Share
10. US General Anesthesia Drugs Market, By Route of Administration, 2019-2033 (USD Million)
10.1. US General Anesthesia Drugs Market Size and Market Share By Route of Administration (2019-2026)10.2. US General Anesthesia Drugs Market Size and Market Share By Route of Administration (2027-2033)
11. US General Anesthesia Drugs Market, By End User, 2019-2033 (USD Million)
11.1. US General Anesthesia Drugs Market Size and Market Share By End User (2019-2026)11.2. US General Anesthesia Drugs Market Size and Market Share By End User (2027-2033)
12. US General Anesthesia Drugs Market, By Region, 2019-2033 (USD Million)
12.1. US General Anesthesia Drugs Market Size and Market Share By Region (2019-2026)12.2. US General Anesthesia Drugs Market Size and Market Share By Region (2027-2033)12.3. Central Region12.4. North Region12.5. South Region
13. Company Profile
13.1. Abbott Laboratories
13.1.1. Company details13.1.2. Financial outlook13.1.3. Product summary13.1.4. Recent developments13.2. AbbVie13.2.1. Company details13.2.2. Financial outlook13.2.3. Product summary13.2.4. Recent developments13.3. Akorn13.3.1. Company details13.3.2. Financial outlook13.3.3. Product summary13.3.4. Recent developments13.4. AstraZeneca plc13.4.1. Company details13.4.2. Financial outlook13.4.3. Product summary13.4.4. Recent developments13.5. Baxter International Inc.13.5.1. Company details13.5.2. Financial outlook13.5.3. Product summary13.5.4. Recent developments13.6. Gilead Sciences, Inc13.6.1. Company details13.6.2. Financial outlook13.6.3. Product summary13.6.4. Recent developments13.7. Heritage Pharmaceuticals Inc.13.7.1. Company details13.7.2. Financial outlook13.7.3. Product summary13.7.4. Recent developments13.8. Novartis AG13.8.1. Company details13.8.2. Financial outlook13.8.3. Product summary13.8.4. Recent developments13.9. Par Pharmaceutical13.9.1. Company details13.9.2. Financial outlook13.9.3. Product summary13.9.4. Recent developments13.10. Pfizer Inc.13.10.1. Company details13.10.2. Financial outlook13.10.3. Product summary13.10.4. Recent developments13.11. Others
14. List of Abbreviations
15. Reference Links
16. Conclusion
17. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
US General Anesthesia Drugs Market is projected to reach USD 3.18 billion by 2033, growing at a CAGR of 3.6% during the forecast period.
US General Anesthesia Drugs Market size from 2022. The Market is expected to reach USD 3.18 billion by 2033, at a CAGR of 3.6% during the forecast period.
US General Anesthesia Drugs Market CAGR of 3.6% during the forecast period.
You can get the sample pages by clicking the link - Click Here
US General Anesthesia Drugs Market size is 3.18 billion from 2023 to 2033.
US General Anesthesia Drugs Market Segment is covered By Form, By Purity, By End User.
The North America is anticipated to have the highest market share in the US General Anesthesia Drugs Market.
"The key players in the market include Companies Covered Abbott Laboratories, AbbVie, Akorn, AstraZeneca plc, Baxter International Inc., Gilead Sciences, Inc, Heritage Pharmaceuticals Inc., Novartis AG, Par Pharmaceutical, Pfizer Inc., Others."
the US FDA released cautions in April 2017. Although the FDA highlighted concerns about the possible dangers associated with repeated or prolonged use.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
